Key Pharmacologic Principles and Drug-Drug Interactions in HIV Patient Care

  • Authors: Amanda H. Corbett, PharmD, BCPS, FCCP; Colin I. Sheffield, PharmD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 6/1/18 (What's New)

Supporting Assets

Table 1 | Table 2 | Table 3 | Table 4 | Table 5 | Table 6 | Table 7 | Table 8 | Table 9 | Table 10 | Table 11 | Table 12 | Table 13

Table 1. Antiretroviral Inhibitors or Inducers of CYP 450 Enzymes

Drug

Substrate

Inhibitor

Inducer

NNRTIs

Efavirenz

2B6 (primary), 2A6, 3A4

2C9, 2C19

3A4, 2B6

Etravirine

3A4, 2C9, 2C19

2C9, 2C19

3A4

Nevirapine

3A4, 2B6

 

3A4, 2B6

Rilpivirine

3A4

 

 

PIs

Atazanavir

3A4

3A4, 2C8 (weak)

 

Fosamprenavir

3A4

3A4 (in vitro)

3A4 (weak, in vivo)

Darunavir

3A4

3A4

 

Lopinavir/ritonavir

3A4

3A4

Saquinavir

3A4

3A4

 

Tipranavir

3A4

2D6

34A, 1A2, 2C19

Integrase Inhibitors

Elvitegravir

3A4

 

Raltegravir

 





 Dolutegravir
3A4
   
Bictegravir
3A4
   

CCR5 Antagonists

Maraviroc

3A4





Boosting Agents

Cobicistat

3A4

3A4, 2D6

 

Ritonavir

3A4, 2D6

3A4, 2D6

1A2, 2C8, 
2C9

...

Action required